{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T04:33:50Z","timestamp":1771907630217,"version":"3.50.1"},"reference-count":43,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.14987","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T08:44:14Z","timestamp":1742546654000},"page":"1-10","source":"Crossref","is-referenced-by-count":2,"title":["Treatment outcomes and safety of reduced\u2011dose venetoclax plus antifungal agents to treat acute myeloid leukemia: A single hospital experience in Taiwan"],"prefix":"10.3892","volume":"29","author":[{"given":"Sheng-Yen","family":"Hsiao","sequence":"first","affiliation":[{"name":"Division of Hematology\u2011Oncology, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan 736402, Taiwan, R.O.C."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Yu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Chi Mei Medical Center, Liouying, Tainan 736402, Taiwan, R.O.C."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Tsung","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2011Oncology, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan 736402, Taiwan, R.O.C."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Yao","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2011Oncology, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan 736402, Taiwan, R.O.C."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2011Oncology, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan 736402, Taiwan, R.O.C."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng-Song","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chi Mei Medical Center, Liouying, Tainan 736402, Taiwan, R.O.C."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"key20250730121637_b1-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/nrd2658","article-title":"Bcl-2 family antagonists for cancer therapy","volume":"7","author":"Lessene","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"key20250730121637_b2-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrc2297","article-title":"Diagnosing and exploiting cancer's addiction to blocks in apoptosis","volume":"8","author":"Letai","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"key20250730121637_b3-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.bcp.2008.06.009","article-title":"Bcl-2 family members as molecular targets in cancer therapy","volume":"76","author":"Marzo","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"key20250730121637_b4-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.imlet.2013.09.015","article-title":"Reprogramming cell death: Bcl2 family inhibition in hematological malignancies","volume":"155","author":"Scarf\u00f2","year":"2013","journal-title":"Immunol Lett"},{"key":"key20250730121637_b5-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","article-title":"The bcl2 selective inhibitor venetoclax induces rapid onset apoptosis of cll cells in patients via a tp53-independent mechanism","volume":"127","author":"Anderson","year":"2016","journal-title":"Blood"},{"key":"key20250730121637_b6-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1080\/10428194.2019.1605511","article-title":"Mantle cell lymphoma: Therapeutic options in transplant-ineligible patients","volume":"60","author":"Robak","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"key20250730121637_b7-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/refractory multiple myeloma: A review of available therapies and clinical scenarios encountered in myeloma relapse","volume":"30","author":"Bhatt","year":"2023","journal-title":"Curr Oncol"},{"key":"key20250730121637_b8-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s44228-023-00041-x","article-title":"Venetoclax: A new partner in the novel treatment era for acute myeloid leukemia and myelodysplastic syndrome","volume":"5","author":"El-Cheikh","year":"2023","journal-title":"Clin Hematol Int"},{"key":"key20250730121637_b9-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/hon.3122","article-title":"Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience","volume":"41","author":"Laurenti","year":"2023","journal-title":"Hematol Oncol"},{"key":"key20250730121637_b10-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/S1470-2045(18)30414-5","article-title":"Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (cll2-bag): Primary endpoint analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Cramer","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20250730121637_b11-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"key20250730121637_b12-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (cll14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20250730121637_b13-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"key20250730121637_b14-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (bellini): A randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20250730121637_b15-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus ldac for newly diagnosed aml ineligible for intensive chemotherapy: A phase 3 randomized place-bo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"key20250730121637_b16-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with flag-ida induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20250730121637_b17-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41408-021-00555-8","article-title":"6-month follow-up of viale-c demonstrates improved and durable efficacy in patients with untreated aml ineligible for intensive chemotherapy (141\/150)","volume":"11","author":"Wei","year":"2021","journal-title":"Blood Cancer J"},{"key":"key20250730121637_b18-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: Primary analysis results from the minimal residual disease cohort of the randomized phase ii captivate study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20250730121637_b19-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jjco\/hyab170","article-title":"Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy","volume":"52","author":"Yamamoto","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"key20250730121637_b20-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"key":"key20250730121637_b21-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"236","DOI":"10.37201\/req\/013.2023","article-title":"Recommendations on the use of azole antifungals in hematology-oncology patients","volume":"3","author":"Azanza","year":"2023","journal-title":"Rev Esp Quimioter"},{"key":"key20250730121637_b22-ol-29-5-14987","article-title":"Drug development and drug interactions: Table of substrates, inhibitors and inducers","author":"U.S. Food and Drug Administration (FDA)","year":"2024","journal-title":"FDA, Silver Spring, MD"},{"key":"key20250730121637_b23-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Br\u00fcggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key20250730121637_b24-ol-29-5-14987","article-title":"Venetoclax prescribing information","author":"U.S. Food and Drug Administration (FDA)"},{"key":"key20250730121637_b25-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: Evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther"},{"key":"key20250730121637_b26-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"107373","DOI":"10.1016\/j.leukres.2023.107373","article-title":"Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: A phase 2 study","volume":"133","author":"De la Garza-Salazar","year":"2023","journal-title":"Leuk Res"},{"key":"key20250730121637_b27-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"key20250730121637_b28-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"key20250730121637_b29-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the UK MRC trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"key20250730121637_b30-ol-29-5-14987","article-title":"Terminology Criteria for Adverse Events (CTCAE)","author":"National Cancer Institute","journal-title":"Version 5.0"},{"key":"key20250730121637_b31-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of aml in adults: 2017 eln recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"key20250730121637_b32-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"key":"key20250730121637_b33-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"key":"key20250730121637_b34-ol-29-5-14987","article-title":"Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Acute myeloid leukemia, Version (3.2024)","author":"National comprehensive cancer network (NCCN)","year":"2024","journal-title":"NCCN, Plymouth Meeting, PA"},{"key":"key20250730121637_b35-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"10","author":"Aldoss","year":"2019","journal-title":"Blood Adv"},{"key":"key20250730121637_b36-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"ofac486","DOI":"10.1093\/ofid\/ofac486","article-title":"Incidence of invasive fungal infections in patients with previously untreated acute myeloid leukemia receiving venetoclax and azacitidine","volume":"9","author":"Zhang","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"key20250730121637_b37-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"6260","DOI":"10.3390\/ijms23116260","article-title":"Venetoclax induces cardiotoxicity through modulation of oxidative-stress-mediated cardiac inflammation and apoptosis via NF-\u03baB and BCL-2 pathway","volume":"23","author":"AlAsmari","year":"2022","journal-title":"Int J Mol Sci"},{"key":"key20250730121637_b38-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00228-017-2403-3","article-title":"Impact of ritonavir dose and schedule on cyp3a inhibition and venetoclax clinical pharmacokinetics","volume":"74","author":"Freise","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"key20250730121637_b39-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bcp.13175","article-title":"Effect of ketoconazole, a strong cyp3a inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-hodgkin lymphoma","volume":"83","author":"Agarwal","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"key20250730121637_b40-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/10781552221110826","article-title":"Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome p450 inhibitor","volume":"29","author":"De la Garza-Salazar","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"key20250730121637_b41-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/bcp.15590","article-title":"Cytochrome p450 inhibition to decrease dosage and costs of venetoclax and ibrutinib: A proof-of-concept case study","volume":"89","author":"De la Garza-Salazar","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"key20250730121637_b42-ol-29-5-14987","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00280-020-04179-w","article-title":"Dose adjustment of venetoclax when co-administered with posaconazole: Clinical drug-drug interaction predictions using a pbpk approach","volume":"87","author":"Bhatnagar","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20250730121637_b43-ol-29-5-14987","first-page":"1","article-title":"Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia","volume":"39","author":"Kobayashi","year":"2022","journal-title":"Oncology"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:16:44Z","timestamp":1753867004000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.14987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,21]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.14987","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]}}}